SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Christina Ha  ¹     Leonardo Salese  ²     Chinyu Su  ²     Krisztina Barbara Gecse  ³     John C. Woolcott  ³     Rajiv Mundayat  ⁴     David P. Hudesman  ⁵     Jerome Paulissen  ⁶     Walter Reinisch  ^7    
1 Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, United States
² Pfizer Inc, Collegeville, United States
³ Amsterdam UMC, Amsterdam, Netherlands
⁴ Pfizer Inc, New York, United States
⁵ Inflammatory Bowel Disease Center at NYU Langone Health, NYU School of Medicine, New York, United States
⁶ Syneos Health, Morrisville, United States
⁷ Medical University of Vienna, Vienna, Austria

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)